Nassif Mikheal, the CEO of Neogen Corp, has made a significant personal investment by acquiring 505 shares of the company’s common stock. This transaction, reported on October 9, 2026, is valued at $11.95 per share, bringing Mikheal's total ownership to 1,579 shares.
This acquisition is noteworthy as it reflects Mikheal's ongoing commitment to Neogen Corp, a company that specializes in in vitro and in vivo diagnostic substances. Such investments by company executives can often signal confidence in the firm’s future prospects and performance.
Background
Neogen Corp, identified by CIK 0000711377, operates in the in vitro and in vivo diagnostic substances sector. The company is incorporated in Michigan and has its fiscal year ending on May 31. As an entity within the life sciences industry, Neogen plays a vital role in health and safety diagnostics.
What the Filing Says
The filing indicates that Mikheal acquired 505 shares on October 9, 2026, and now owns a total of 1,579 shares. The filing states, “The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.”
Impact
This transaction may affect Neogen's stakeholders, including investors and employees, as it showcases the CEO's investment in the company. Such actions can influence market perceptions and employee morale, reflecting leadership confidence in the company’s direction.
What's Next
The filing does not say what happens next.